{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T13:12:48Z","timestamp":1783861968871,"version":"3.55.0"},"reference-count":36,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background and Objectives: The effective treatment of chronic myeloid leukemia leads to the restoration of proper immune system function. We aimed to investigate fluctuations in circulating cytokines, angiogenic factors and complement components in patients with CML during the first year of treatment with TKI and correlate them with the degree of achieved molecular response. Material and Methods: We recruited 31 patients with newly diagnosed CML. Peripheral blood and bone marrow samples were obtained, and concentrations of serum proteins were measured using an immunology multiplex assay. Results: The study cohort was divided into two groups of optimal or non-optimal in accordance with the European Leukemia Net (ELN) guidelines. We found significantly higher concentrations of C1q, C4 and C5a in serum after 3 months of TKI treatment in patients who achieved optimal responses in the 6 months after diagnosis. The most alterations were observed during 12 months of therapy. Patients in the optimal response group were characterized by higher serum concentrations of TGF-\u03b2, EGF, VEGF, Angiopoietin 1, IFN-\u03b3 and IL-8. Conclusions: The later plasma concentrations of complement components were significantly increased in patients with optimal responses. The changes after 12 months of treatment were particularly significant. Similar changes in bone marrow samples were observed.<\/jats:p>","DOI":"10.3390\/jcm13082353","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T07:55:54Z","timestamp":1713426954000},"page":"2353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Depth of the Molecular Response in Patients with Chronic Myeloid Leukemia Correlates with Changes in Humoral Immunity"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4656-9318","authenticated-orcid":false,"given":"Micha\u0142","family":"Janowski","sequence":"first","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4008-7473","authenticated-orcid":false,"given":"Karolina","family":"\u0141uczkowska","sequence":"additional","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Gniot","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, 60-569 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-2020","authenticated-orcid":false,"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, 60-569 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9415-2758","authenticated-orcid":false,"given":"Krzysztof","family":"Safranow","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, 40-027 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Machali\u0144ski","sequence":"additional","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7052-9741","authenticated-orcid":false,"given":"Edyta","family":"Paczkowska","sequence":"additional","affiliation":[{"name":"Department of General Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic Myeloid Leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1038\/sj.onc.1206082","article-title":"BCR\/ABL: From Molecular Mechanisms of Leukemia Induction to Treatment of Chronic Myelogenous Leukemia","volume":"21","author":"Salesse","year":"2002","journal-title":"Oncogene"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12185-021-03117-7","article-title":"Treatment-Free Remission and Immunity in Chronic Myeloid Leukemia","volume":"113","author":"Ureshino","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML Patients with Deep Molecular Responses to TKI Have Restored Immune Effectors and Decreased PD-1 and Immune Suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00277-023-05199-1","article-title":"Switching from Imatinib to Nilotinib plus Pegylated Interferon-A2b in Chronic Phase CML Failing to Achieve Deep Molecular Response: Clinical and Immunological Effects","volume":"102","author":"Geelen","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_8","first-page":"137320","article-title":"Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment","volume":"2010","author":"Sterzl","year":"2010","journal-title":"Clin. Dev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1080\/10428194.2017.1344841","article-title":"Association between Proteomic Profile and Molecular Response in Chronic Myeloid Leukemia Patients","volume":"59","author":"Garrisi","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"M\u00e9ndez-Vald\u00e9s, G., G\u00f3mez-Hevia, F., Lillo-Moya, J., Gonz\u00e1lez-Fern\u00e1ndez, T., Abelli, J., Cereceda-Cornejo, A., Bragato, M.C., Saso, L., and Rodrigo, R. (2023). Endostatin and Cancer Therapy: A Novel Potential Alternative to Anti-VEGF Monoclonal Antibodies. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030718"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1179\/102453308X315898","article-title":"Elevated Serum Endostatin Levels Are Associated with Favorable Outcome in Acute Myeloid Leukemia","volume":"13","author":"Aref","year":"2008","journal-title":"Hematology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cncr.10200","article-title":"Clinical Significance of Plasma Endostatin in Acute Myeloid Leukemia\/Myelodysplastic Syndrome","volume":"94","author":"Lai","year":"2002","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Catellani, S., Pierri, I., Gobbi, M., Poggi, A., and Zocchi, M.R. (2011). Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018925"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00432-017-2378-6","article-title":"Tyrosine Kinase Inhibitor Therapy-Induced Changes in Humoral Immunity in Patients with Chronic Myeloid Leukemia","volume":"143","author":"Rajala","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Revel, M., Daugan, M.V., Saut\u00e9s-Fridman, C., Fridman, W.H., and Roumenina, L.T. (2020). Complement System: Promoter or Suppressor of Cancer Progression?. Antibodies, 9.","DOI":"10.3390\/antib9040057"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41568-019-0210-0","article-title":"Context-Dependent Roles of Complement in Cancer","volume":"19","author":"Roumenina","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"958273","DOI":"10.3389\/fimmu.2022.958273","article-title":"C1q as a Target Molecule to Treat Human Disease: What Do Mouse Studies Teach Us?","volume":"13","author":"Schulz","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1080\/10428194.2018.1543883","article-title":"Is Complement C1q a Potential Marker for Tumor Burden and Immunodeficiency in Multiple Myeloma?","volume":"60","author":"Yang","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.2022017046","article-title":"C1Q Labels a Highly Aggressive Macrophage-like Leukemia Population Indicating Extramedullary Infiltration and Relapse","volume":"141","author":"Yang","year":"2023","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Michelis, R., Tadmor, T., Barhoum, M., Shehadeh, M., Shvidel, L., Aviv, A., Stemer, G., Dally, N., Rahimi-Levene, N., and Yuklea, M. (2019). A C5a-Immunoglobulin Complex in Chronic Lymphocytic Leukemia Patients Is Associated with Decreased Complement Activity. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0209024"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cavalcante, M.d.S., Torres-Romero, J.C., Lobo, M.D.P., Moreno, F.B.M.B., Bezerra, L.P., Lima, D.S., Matos, J.C., Moreira, R.d.A., and Monteiro-Moreira, A.C.d.O. (2016). A Panel of Glycoproteins as Candidate Biomarkers for Early Diagnosis and Treatment Evaluation of B-Cell Acute Lymphoblastic Leukemia. Biomark. Res., 4.","DOI":"10.1186\/s40364-016-0055-6"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3892\/or.2012.2045","article-title":"Role of VEGF\/VEGFR in the Pathogenesis of Leukemias and as Treatment Targets (Review)","volume":"28","author":"Song","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107692","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: A Chemokine at the Intersection of Cancer Plasticity, Angiogenesis, and Immune Suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1080\/10428194.2023.2232492","article-title":"Role of IL8 in Myeloid Malignancies","volume":"64","author":"Ramachandra","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2016.09.019","article-title":"Plasma Proteomics in CML Patients before and after Initiation of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity and Loss of Angiogenic Stimuli","volume":"50","author":"Christiansson","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.imlet.2016.09.004","article-title":"Predictive Value of Serum Cytokine Levels in Chronic Myeloid Leukemia Patients","volume":"179","author":"Petrackova","year":"2016","journal-title":"Immunol. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.molonc.2008.07.003","article-title":"The Chemokine Interleukin-8 and the Surface Activation Protein CD69 Are Markers for Bcr\u2013Abl Activity in Chronic Myeloid Leukemia","volume":"2","author":"Hantschel","year":"2008","journal-title":"Mol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/jclinpath-2015-203526","article-title":"TGF\u03b1 Expression in Myeloid Malignancies","volume":"69","author":"Kavanagh","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"ref_29","first-page":"e24835","article-title":"Serum Tumor Necrosis Factor-Alpha Levels in Acute Leukemia and Its Prognostic Significance","volume":"14","author":"Verma","year":"2022","journal-title":"Cureus"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/leu.2016.34","article-title":"TGF-\u03b1 and IL-6 Plasma Levels Selectively Identify CML Patients Who Fail to Achieve an Early Molecular Response or Progress in the First Year of Therapy","volume":"30","author":"Nievergall","year":"2016","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2009.11.008","article-title":"Transforming Growth Factor Beta (TGF-\u03b2) and Inflammation in Cancer","volume":"21","author":"Bierie","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of Transforming Growth Factor-Beta in Hematologic Malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"19107","DOI":"10.1038\/s41598-023-46552-8","article-title":"Comprehensive Characterization of TGFB1 across Hematological Malignancies","volume":"13","author":"Wang","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Aldinucci, D., Borghese, C., and Casagrande, N. (2020). The CCL5\/CCR5 Axis in Cancer Progression. Cancers, 12.","DOI":"10.3390\/cancers12071765"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and Efficacy of the Combination of Pegylated Interferon-A2b and Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients","volume":"30","author":"Stentoft","year":"2016","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bjh.18486","article-title":"Dasatinib plus Peg-Interferon Alpha 2b Combination in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia: Results of a Multicenter Phase 2 Study (DASA-PegIFN Study)","volume":"200","author":"Roy","year":"2023","journal-title":"Br. J. Haematol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/8\/2353\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:30:00Z","timestamp":1760106600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/8\/2353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["jcm13082353"],"URL":"https:\/\/doi.org\/10.3390\/jcm13082353","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}